Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

Similar articles for PubMed (Select 23520448)

1.

A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer.

Wang S, Peng L, Li J, Zeng X, Ouyang L, Tan C, Lu Q.

PLoS One. 2013;8(3):e55917. doi: 10.1371/journal.pone.0055917. Epub 2013 Mar 8.

2.

Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S.

Kumar G, Woods B, Hess LM, Treat J, Boye ME, Bryden P, Winfree KB.

Lung Cancer. 2015 Jun 3. pii: S0169-5002(15)00281-0. doi: 10.1016/j.lungcan.2015.05.020. [Epub ahead of print]

3.

Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany.

Schremser K, Rogowski WH, Adler-Reichel S, Tufman AL, Huber RM, Stollenwerk B.

Pharmacoeconomics. 2015 Jun 17. [Epub ahead of print]

PMID:
26081300
4.

Corrigendum: Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.

Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R.

Health Technol Assess. 2015 May;17(31):281-2. doi: 10.3310/hta17310-c201505.

5.

A Randomized Phase II Study of Erlotinib Plus Nab-Paclitaxel Versus Erlotinib Alone as Second-Line Therapy for Chinese Patients with Advanced EGFR Wild-Type Non-Small-Cell Lung Cancer.

Zhang Y, Gao C, Qu W, Gao Y, Zhu S, Zhang S, He W, Yu Y.

Cancer Invest. 2015 Jul;33(6):241-5. doi: 10.3109/07357907.2015.1024318. Epub 2015 May 7.

PMID:
25951232
6.
7.

How many drugs in the maintenance setting for non-small-cell lung cancer? For what benefit?

Vergnenègre A.

Ann Palliat Med. 2013 Oct;2(4):170-2. doi: 10.3978/j.issn.2224-5820.2013.10.01.

8.

Model-based assessment of erlotinib effect in vitro measured by real-time cell analysis.

Benay S, Meille C, Kustermann S, Walter I, Walz A, Gonsard PA, Pietilae E, Kratochwil N, Iliadis A, Roth A, Lave T.

J Pharmacokinet Pharmacodyn. 2015 Jun;42(3):275-85. doi: 10.1007/s10928-015-9415-3. Epub 2015 Mar 31.

PMID:
25822652
9.

Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer?

Charakidis M, Boyer M.

Transl Lung Cancer Res. 2014 Dec;3(6):395-6. doi: 10.3978/j.issn.2218-6751.2014.09.03. No abstract available.

10.

Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial.

Hornberger J, Hirsch FR, Li Q, Page RD.

Lung Cancer. 2015 May;88(2):223-30. doi: 10.1016/j.lungcan.2015.03.006. Epub 2015 Mar 12.

PMID:
25804732
11.

Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer.

Gharaibeh M, McBride A, Bootman JL, Abraham I.

Br J Cancer. 2015 Apr 14;112(8):1301-5. doi: 10.1038/bjc.2015.65. Epub 2015 Mar 19.

PMID:
25791875
12.

Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study.

Zhou J, Zhao R, Wen F, Zhang P, Tang R, Du Z, He X, Zhang J, Li Q.

Med Oncol. 2015 Apr;32(4):121. doi: 10.1007/s12032-015-0580-4. Epub 2015 Mar 19.

PMID:
25788034
13.
14.

Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.

de Marinis F, Vergnenegre A, Passaro A, Dubos-Arvis C, Carcereny E, Drozdowskyj A, Zeaiter A, Perez-Moreno P, Rosell R.

Future Oncol. 2015;11(3):421-9. doi: 10.2217/fon.14.269.

PMID:
25675123
15.

Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer.

Romanus D, Cardarella S, Cutler D, Landrum MB, Lindeman NI, Gazelle GS.

J Thorac Oncol. 2015 Apr;10(4):586-94. doi: 10.1097/JTO.0000000000000474.

PMID:
25590606
16.

Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review.

Chouaïd C, Crequit P, Borget I, Vergnenegre A.

Clinicoecon Outcomes Res. 2014 Dec 15;7:9-15. doi: 10.2147/CEOR.S43328. eCollection 2015. Review.

17.

Lung cancer in 2014: optimizing lung cancer treatment approaches.

Rosell R, Karachaliou N.

Nat Rev Clin Oncol. 2015 Feb;12(2):75-6. doi: 10.1038/nrclinonc.2014.225. Epub 2014 Dec 23.

PMID:
25533943
18.

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.

Borget I, Pérol M, Pérol D, Lavolé A, Greillier L, Dô P, Westeel V, Crequit J, Léna H, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Chabaud S, Vergnenegre A, Zalcman G, Chouaïd C; IFCT-GFPC investigators.

BMC Cancer. 2014 Dec 15;14:953. doi: 10.1186/1471-2407-14-953.

19.

Personalization of chemotherapy for metastatic pancreatic cancer.

Sasahara YI, Narimatsu H, Suzuki S, Fukui T, Sato H, Shirahata N, Yoshioka T.

Clin Med Insights Case Rep. 2014 Jul 24;7:59-61. doi: 10.4137/CCRep.S14478. eCollection 2014.

20.

Regression analysis of indicating multiple incremental cost-effectiveness ratios for non-small cell lung cancer treatment.

Nakahara N, Kamae I.

J Med Econ. 2014 Aug;17(8):547-54. doi: 10.3111/13696998.2014.923890. Epub 2014 May 29.

PMID:
24826807
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk